Despite weak quarterly results, Balaxi Pharmaceuticals Ltd. — a Hyderabad, India-based pharmaceutical company focused on branded formulations in emerging markets — witnessed a 14.5% surge in share price on June 2, 2025. The sharp movement comes after the company reported a widened net loss for Q4 FY25, while full-year FY25 profit held steady. Investor activity and recent bulk deals likely triggered the stock’s rally.
Balaxi Pharmaceuticals Ltd., a Hyderabad-based pharmaceutical company known for its portfolio of branded formulations targeting emerging markets, saw its shares jump 14.5% on June 2, 2025. The surge came even as the company reported a net loss of ₹117.85 lakh for the fourth quarter ended March 2025 (Q4 FY25).
The company’s total income dropped sharply to ₹996.98 lakh in Q4 FY25, down 37.9% from ₹1,606.86 lakh in Q4 FY24. Sequentially, income also fell 29% from ₹1,407.49 lakh in Q3 FY25. The quarterly bottom line shifted from a net profit of ₹174.32 lakh in Q3 to a loss in Q4, highlighting continued margin pressure and rising operational costs.
For the full financial year (FY25), Balaxi reported a marginally lower net profit of ₹360.13 lakh compared to ₹365.04 lakh in FY24 — a 1.3% year-on-year drop. Revenue from operations declined 5.6% to ₹6,098.82 lakh in FY25 from ₹7,019.60 lakh a year earlier.
Despite the financial setback, investor sentiment seemed bolstered by earlier bulk deal activity. On March 3, 2025, Ebisu Global Opportunities Fund Ltd. and Unico Global Opportunities Fund Ltd. each acquired over 45 lakh shares at ₹53 per share. These purchases matched shares sold by MGC Fund Ltd. and Elala India Opportunities Fund, triggering renewed market interest.
Although Balaxi Pharma’s shares traded below ₹60, the stock has been under pressure over the past year, losing more than 58% of its value. It declined 9% in May and 14% in April, with a brief 20% rebound in March, following a prolonged seven-month slump between August 2024 and February 2025.
Balaxi Pharmaceuticals continues to focus on expanding its global footprint, with product offerings across Latin America, Africa, and the Caribbean. The company’s strategic focus on intellectual property-backed branded drugs in underserved markets positions it uniquely despite current financial challenges.
